Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 12/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25363108 | 0.92 | FURIN (0.38) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL26026790 | 0.92 | FURIN (0.38) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25363100 | 0.92 | FURIN (0.38) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25361709 | 0.91 | FURIN (0.37) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25360798 | 0.91 | FURIN (0.37) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25359008 | 0.91 | CTSL (0.38) | FURINROCK2CTSL | |
| SCHEMBL29623561 | 0.90 | FURIN (0.40) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25709382 | 0.90 | FURIN (0.40) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL29528370 | 0.90 | FURIN (0.40) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL30483106 | 0.89 | FURIN (0.40) | FURINROCK2MAP1LC3BHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | FURIN 2087/4885ROCK2 2442/4885MAP1LC3B 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.